Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral β-lactams

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 3, 2003, Pages 691-696

  Van Kerkhoven, D ^a   Peetermans, W E ^a   Verbist, L ^a   Verhaegen, Jan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

lactams; Breakthrough bacteraemia; Macrolides; S. pneumoniae

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFADROXIL; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; GENTAMICIN; MACROLIDE; OFLOXACIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TETRACYCLINE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BELGIUM; CLINICAL OBSERVATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG USE; FEMALE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NONHUMAN; OUTPATIENT CARE; PENICILLIN RESISTANCE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; BETA-LACTAM RESISTANCE; BETA-LACTAMS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 0037341685     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg116     Document Type: Article

References (23)

1. Prevention of Pneumococcal Disease. (1997). Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 46, 1-19.
2. Appelbaum, P. C. (2000). Microbiological and pharmacodynamic considerations in the treatment of infections due to antimicrobial-resistant Streptococcus pneumoniae. Clinical Infectious Diseases 31, Suppl. 2, S29-34.
3. Verhaegen, J., Van de Ven, J., Verbiest, N., Van Eldere, J. & Verbist, L. (2000). Evolution of Streptococcus pneumoniae sero-types and antibiotic resistance in Belgium-update (1994-98). Clinical Microbiology and Infectious Diseases 6, 308-15.
4. Leclercq, R. (2002). Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clinical Infectious Diseases 34, 482-92.
5. Lagrou, K., Peetermans, W. E., Verhaegen, J., Van Lierde, S., Verbiest, L. & Van Eldere, J. (2002). Macrolide resistance in Belgian Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 45, 119-21.
6. Lonks, J. R., Garau, J., Gomez, L., Xercavins, M., Ochoa de Echagüen, A., Gareen, I. F. et al. (2002). Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clinical Infectious Diseases 35, 556-64.
7. File, T. M., Jr (2002). Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of β-lactam-resistant Streptococcus pneumoniae. Clinical Infectious Diseases 34, Suppl. 1, S17-26.
8. National Committee for Clinical Laboratory Standards. (2002). Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard M100. NCCLS, Villanova, PA, USA.
9. The European Antimicrobial Resistance Surveillance System (EARSS) Newsletter, no. 4, January 2002. RIVM, Bilthoven, The Netherlands.
10. Verhaegen, J., Glupczynski, Y., Verbist, L., Blogie, M., Verbiest, N., Vandeven, J. et al. (1995). Capsular types and antibiotic susceptibility of pneumococci isolated from patients in Belgium with serious infections, 1980-1993. Clinical Infectious Diseases 20, 1339-45.
11. García-Rey, C., Aguilar, L., Baquero, F., Casal, J. & Dal-Ré, R. (2002). Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. Journal of Clinical Microbiology 40, 159-64.
12. Pihlajamäki, M., Kotilainen, P., Kaurila, T., Klaukka, T., Palva, E., Hovinen, P. et al. (2001). Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. Clinical Infectious Diseases 33, 483-8.
13. Ferrero, J. L., Bopp, B. A., Marsh, K. C., Quigley, S. C., Johnson, M. J., Anderson, D. J. et al. (11990). Metabolism and disposition of clarithromycin in man. Drug Metabolism and Disposition 18, 441-6.
14. Dagan, R., Piglansky, L., Yagupsky, P., Fliss, D. M., Lieberman, A. & Leibovitz, E. (1997). Bacteriology response in acute otitis media: comparison between azithromycin, cefaclor and amoxicillin. In Program and Abstracts of the Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 1997. Abstract K-103. American Society for Microbiology, Washington, DC, USA.
15. Kelley, M. A., Weber, D. J., Gilligan, P. & Cohen, M. S. (2000). Breakthrough pneumococcal bacteraemia in patients being treated with azithromycin and clarithromycin. Clinical Infectious Diseases 31, 1008-11.
16. Fogarty, C., Goldschmidt, R. & Bush, K. (2000). Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clinical Infectious Diseases 31, 613-5.
17. Craig, W. A. (1998). Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases 26, 1-12.
18. Verhaegen, J. & Verbist, L. (1998). In vitro activity of 21 β-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 41, 381-5.
19. Feikin, D. R., Schuchat, A., Kolczak, M., Barrett, N. L., Harrison, L. H., Lefkowitz, L. et al. (2000). Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. American Journal of Public Health 90, 223-9.
20. Metlay, J. P., Hofmann, J., Cetron, M. S., Fine, M. J., Farley, M. M., Whitney, C. et al. (2000). Impact of penicillin susceptibility on medical outcomes for adult patients with bacteraemic pneumococcal pneumonia. Clinical Infectious Diseases 30, 520-8.
21. Bartlett, J. G., Dowell, S. F., Mandell, L. A., File, T. M., Jr, Musher, D. M. & Fine, M. J. (2000). Practice guidelines for the management of community-acquired pneumonia in adults. Clinical Infectious Diseases 31, 347-82.
22. Niederman, M. S., Mandell, L. A., Anzueto, A., Bass, J. B., Broughton, W. A., Campbell, G. D. et al. (2001). Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy and prevention. American Journal of Respiratory and Critical Medicine 163, 1730-54.
23. Guillemot, D., Carbon, C., Balkau, B., Geslin, P., Lecoeur, H., Vauzelle-Kervroedan, F. et al. (1998). Low dosage and long treatment duration of β-lactam. Risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. Journal of the American Medical Association 279, 365-70.